NPS Pharmaceuticals to Report First Quarter 2014 Financial Results
April 29 2014 - 4:10PM
Business Wire
NPS Pharmaceuticals, Inc. (Nasdaq:NPSP) announced today that it
will report its first quarter 2014 financial results on Thursday,
May 8, 2014 at approximately 8:00 a.m. ET. The press release will
be followed by a conference call and webcast at 8:30 a.m. ET.
To participate in the conference call, dial (800) 638-4817 and
use passcode 47278807. International callers may dial +1 (617)
614-3943, using the same passcode. In addition, a live audio of the
conference call will be available over the Internet. Interested
parties can access the event through the investors’ calendar of
events page on the NPS website at http://www.npsp.com/calendar.
If you are unable to participate in the live call, a replay will
be available at (888) 286-8010, with passcode 75535471 until
midnight ET, May 22, 2014. International callers may access the
replay by dialing +1 (617) 801-6888, using the same passcode. The
webcast will also be available through the NPS website for the same
period.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a global biopharmaceutical company
pioneering and delivering therapies that transform the lives of
patients with rare diseases. The company’s lead product, Gattex®
(teduglutide [rDNA origin]) for injection is approved in the US for
adult patients with Short Bowel Syndrome (SBS) who are dependent on
parenteral support. In the EU, teduglutide (trade name: Revestive®)
is approved for the treatment of adult patients with SBS; patients
should be stable following a period of intestinal adaptation after
surgery. Teduglutide is not approved for the treatment of pediatric
SBS patients. The safety and efficacy of teduglutide in this
population is currently being evaluated in a global registration
trial. A Biologics License Application is undergoing FDA review for
Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism, a
rare endocrine disorder characterized by insufficient levels of
parathyroid hormone. The Prescription Drug User Fee Act goal date
for the Natpara application is October 24, 2014. NPS’ earlier stage
pipeline includes NPSP795, a calcilytic compound with potential
application in rare disorders involving increased calcium sensing
receptor activity, such as autosomal dominant hypocalcemia (ADH).
NPS complements its proprietary programs with a royalty-based
portfolio of products and product candidates that includes
agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals,
and Kyowa Hakko Kirin.
NPS Pharmaceuticals, Inc.Gail Brophy, 908-450-5335
Nps (NASDAQ:NPSP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nps (NASDAQ:NPSP)
Historical Stock Chart
From Jul 2023 to Jul 2024